A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda

被引：0
|
作者：
Solomon J. Lubinga
Byamah B. Mutamba
Angelo Nganizi
Joseph B. Babigumira
机构：
[1] University of Washington,Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy
[2] University of Washington,Global Medicines Program, Department of Global Health
[3] Butabika National Referral Hospital for Mental,undefined
[4] Neurological and Substance Abuse Disorders,undefined
[5] Kadic Hospital,undefined
来源：
Applied Health Economics and Health Policy | 2015年 / 13卷
关键词：
Schizophrenia; Haloperidol; Risperidone; Olanzapine; Quetiapine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：493 / 506
页数：13
相关论文
共 50 条
  • [41] VALIDATING A COST-EFFECTIVENESS ANALYSIS COMPARING OLANZAPINE WITH ZIPRASIDONE IN THE TREATMENT OF SCHIZOPHRENIA
    Graham, C.
    Mauskopf, J.
    Lawson, A. H.
    Ascher-Svanum, H.
    Bruhn, D.
    Watson, P. R.
    VALUE IN HEALTH, 2010, 13 (03) : A113 - A113
  • [42] Cost-effectiveness analysis of ziprasidone versus no treatment for schizophrenia relapse prevention
    Azanza, JR
    Bernardo, M
    Rubio-Terrés, C
    Díez, T
    Rejas, J
    VALUE IN HEALTH, 2005, 8 (06) : A204 - A204
  • [43] Schizophrenia treatment in the developing world:: an interregional and multinational cost-effectiveness analysis
    Chisholm, Dan
    Gureje, Oye
    Saldivia, Sandra
    Calderon, Marcelo Villalon
    Wickremasinghe, Rajitha
    Mendis, Nalaka
    Ayuso-Mateos, Jose-Luis
    Saxena, Shekhar
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2008, 86 (07) : 542 - 551
  • [44] LONG-TERM COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS FOR SCHIZOPHRENIA IN THE UNITED STATES
    Rajagopalan, K.
    O'Day, K.
    Meyer, K.
    Pikalov, A. A., III
    Loebel, A.
    VALUE IN HEALTH, 2012, 15 (04) : A87 - A87
  • [45] A Cost-Effectiveness Analysis of a Pediatric Operating Room in Uganda
    Yap, Ava
    Muzira, Arlene
    Cheung, Maija
    Healy, James
    Kakembo, Nasser
    Kisa, Phyllis
    Cunningham, David
    Youngson, George
    Sekabira, John
    Yaesoubi, Reza
    Ozgediz, Doruk
    SURGERY, 2018, 164 (05) : 953 - 959
  • [46] COST-EFFECTIVENESS OF PALIPERIDONE PALMITATE LONG -ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA IN PERU
    Longaray, E.
    Guerrero, E.
    Aguirre, A.
    Hernandez, J.
    VALUE IN HEALTH, 2018, 21 : S185 - S185
  • [47] COST-EFFECTIVENESS OF PALIPERIDONE PALMITATE FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY
    Zeidler, J.
    Mahlich, J. C.
    Greiner, W.
    Heres, S.
    VALUE IN HEALTH, 2013, 16 (07) : A547 - A547
  • [48] COST-EFFECTIVENESS OF PALIPERIDONE PALMITATE FOR THE TREATMENT OF SCHIZOPHRENIA IN MEXICO
    Reyes-Lopez, A.
    Querol, J.
    VALUE IN HEALTH, 2011, 14 (07) : A561 - A561
  • [49] Cost and Cost-Effectiveness of a Digital Adherence Technology for Tuberculosis Treatment Support in Uganda
    Thompson, Ryan R.
    Kityamuwesi, Alex
    Kuan, Alice
    Oyuku, Denis
    Tucker, Austin
    Ferguson, Olivia
    Tinka, Lynn Kunihira
    Crowder, Rebecca
    Turyahabwe, Stavia
    Cattamanchi, Adithya
    Dowdy, David W.
    Katamba, Achilles
    Sohn, Hojoon
    VALUE IN HEALTH, 2022, 25 (06) : 924 - 930
  • [50] ANALYSIS OF COST EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA BASED ON NNT (NUMBER NEEDED TREAT)
    Pereira, M.
    Duchesne, I
    VALUE IN HEALTH, 2009, 12 (07) : A521 - A521
12345